Appointed
Loren Mark Katzovitz
Director
VERU ·
VERU INC.
appointed Loren Mark Katzovitz to fill the vacancy created thereby.
Ready 8-Ks
50
Latest filing
September 8, 2026, 8:17 AM ET
Top materiality
0.95
Event mix
other_material ×27 · earnings ×12 · regulatory ×5
Sentiment
8 pos · 11 neg · 31 neu
Latest earnings
reported 2024-Q2
Executive change
recent →
Recent 8-K filings for VERU
Highest-materiality recent filing
VERU restates Q3 FY2023 results; recognizes material weakness, going concern doubt
- Gain on sale of ENTADFI assets overstated by ~$12.7M; corrected gain is $4.7M.
- $14M in notes receivable improperly recorded; should not have been recognized due to collectability uncertainty.
-
Veru pivots sabizabulin to daraxonrasib-resistant pancreatic cancer; drops cardiovascular program
Sabizabulin showed potent activity (IC50=18.2nM) in daraxonrasib-resistant KRAS pancreatic cancer cells; resistance index 0.25 vs 68 for daraxonrasib.
-
Veru reports Q3 FY2026 net loss $7.0M; PLATEAU trial fully enrolled with 239 patients
Q3 net loss $7.0M ($0.30/share) vs $7.3M ($0.50/share) prior year; operating loss $7.7M.
-
Veru enters $21.8M at-the-market equity offering with Oppenheimer and Canaccord
Up to $21.8M of common stock may be sold from time to time via ATM offering.
-
Veru enters clinical supply deal with Novo Nordisk for Phase 2b combo study of enobosarm + Wegovy
Veru sponsors Phase 2b PLATEAU study testing enobosarm + Wegovy in older adults with obesity on GLP-1 therapy.
-
Veru Q1 net loss narrows to $5.3M; cash $33M; Phase 2b obesity trial on track
Net loss of $5.3M ($0.26 per share) vs $8.9M ($0.61) in Q1 FY2025.
-
Veru reports FY2025 net loss $22.7M, cash $15.8M; enobosarm Phase 2b PLATEAU to start Q1'26
Net loss from continuing ops $15.7M ($1.07/sh) vs $35.3M ($2.61/sh) prior year; total net loss $22.7M ($1.55/sh).
-
Offering includes 1.4M common shares + 7M pre-funded warrants and 8.4M Series A and 8.4M Series B warrants at $3.00/unit.
-
Veru regains Nasdaq minimum bid price compliance; delisting risk removed
Received Nasdaq letter on August 26, 2025 confirming compliance with Listing Rule 5550(a)(2).
-
Veru Q3 net loss narrows to $0.50/sh; enobosarm Phase 2b data show lean mass preservation
Net loss from continuing ops $7.3M ($0.50/sh) vs $10.3M ($0.71/sh) in Q3 2024.
-
Veru shareholders approve reverse stock split at ratio of 1-for-2 to 1-for-20
Shareholders voted 98,869,209 for, 7,080,957 against, 1,013,920 abstain on reverse split proposal.
-
Veru's enobosarm Phase 2b meets primary endpoint; 71% less lean mass loss with GLP-1
Phase 2b QUALITY study met primary endpoint: 71% relative reduction in lean mass loss with enobosarm + semaglutide vs placebo (p=0.002).
-
Veru receives Nasdaq extension to Aug 25, 2025 to regain $1.00 bid price compliance
Nasdaq granted Veru additional 180 days, until August 25, 2025, to meet minimum $1.00 closing bid price requirement.
-
Veru reports Q1 net loss $8.9M; positive Phase 2b enobosarm data; FC2 business sold for $18M
Net loss from continuing ops $1.8M ($0.01/sh) vs $7.7M; overall net loss $8.9M ($0.06/sh) vs $8.3M.
-
Veru Inc. sells FC2 female condom business for $18M, netting ~$12.5M after change-of-control payment
Sold FC2 female condom business to Clear Future, Inc., for $18M cash, subject to working capital adjustment.
-
Veru amends forbearance with Onconetix; extends note maturities, adjusts payment terms
Veru entered amended forbearance agreement with Onconetix for two promissory notes totaling $10M principal.
-
Veru receives Nasdaq minimum bid price deficiency notice; 180-day cure period until Feb 25, 2025
Nasdaq notified Veru on Aug 29, 2024 that common stock bid price was below $1.00 for 30 consecutive business days.
-
Q3 net revenue $4.0M (up 21% YoY); operating loss $10.9M vs $13.7M.
-
Veru dismisses RSM as auditor; engages Cherry Bekaert; cites material weaknesses
RSM US LLP dismissed as independent auditor on May 16, 2024; no disagreements reported.
-
Veru reports Q2 fiscal 2024 net loss $10M, cash $34.7M; enobosarm Phase 2b enrolling
Fiscal Q2 net revenues $4.1M (down 38% YoY); net loss $10.0M ($0.07/share) vs $33.8M loss ($0.42) prior year.
-
Veru enters forbearance with Onconetix on $10M notes after default
Onconetix defaulted on $5M April 2024 note due Apr 19, 2024; Veru forbears until Mar 31, 2025.
-
Veru regains Nasdaq minimum bid price compliance; non-compliance remedied
Received Nasdaq notice on April 23, 2024 confirming compliance with Listing Rule 5550(a)(2).
-
Veru receives Nasdaq delisting notice for delayed Q1 10-Q filing
Veru received a Nasdaq deficiency letter for failing to file Q1 FY2024 10-Q (quarter ended Dec 31, 2023) on time.
-
Veru restates FY2023 financials for R&D expense overstatement; cash runway extends
Audit committee concludes FY2023 financials cannot be relied upon due to overestimated R&D expenses.
-
Veru reports Q1 revenue $2.1M, cash $40.6M; FDA clears IND for enobosarm with GLP-1 for weight loss
Net revenue $2.1M (down from $2.5M YoY); gross profit $1.2M (up from $0.7M).
-
Nasdaq notified Veru on Jan 25, 2024 that its closing bid price was below $1.00 for 30 consecutive business days.
-
Veru prices public offering of 45.8M shares at $0.72, net proceeds ~$35.2M for enobosarm trial
Entered underwriting agreement for 45,833,333 shares at $0.72/share; gross proceeds ~$33M.
-
VERU restates Q3 FY2023 results; recognizes material weakness, going concern doubt
Gain on sale of ENTADFI assets overstated by ~$12.7M; corrected gain is $4.7M.
-
Enobosarm monotherapy achieved 2 PR/16 (12.5%) ORR vs 0 PR/18 for active control in discontinued Phase 3 ARTEST trial.
-
Veru Q3 net income $6.3M on ENTADFI gain; pipeline updates for enobosarm, sabizabulin
Net income $6.3M ($0.07/diluted share) vs net loss $22.2M ($0.28) in Q3 2022; revenue $3.3M down from $9.6M.
-
Veru enters into $75M ATM equity offering agreement with Jefferies
Entered Open Market Sale Agreement with Jefferies to sell up to $75M of common stock in at-the-market offerings.
-
Net loss $38.8M vs $14.2M YoY; operating loss $39.4M including $3.9M impairment and $3.9M credit loss provision.
-
Veru signs $100M common stock purchase agreement with Lincoln Park Capital
Up to $100M of common stock over 36 months; regular purchases ≤225,000 shares/day.
-
Veru sells ENTADFI assets to Blue Water Vaccines for $20M upfront + up to $80M milestones
Asset purchase closed April 19, 2023; buyer paid $6M at closing, owes $4M in FY2023 and $10M in FY2024.
-
Veru Inc. raises $5M via private placement of 5M shares at $1.00 to Frost Gamma Investments Trust
Issued 5,000,000 shares of common stock at $1.00 per share to Frost Gamma Investments Trust for total proceeds of $5,000,000.
-
Veru's contract with largest FC2 customer The Pill Club terminated after payment default
The Pill Club accounted for 44% of Veru's net revenues in fiscal 2022 and 43% in 2021.
-
Terminating Phase 3 VERACITY trial of sabizabulin in prostate cancer; pausing Phase 2 Veru-100 and zuclomiphene development.
-
Veru reports Q1 FY2023 net loss of $36.8M; revenue falls 82% to $2.5M
Net revenues decreased to $2.5M from $14.1M in prior-year quarter; gross profit fell to $0.7M.
Executive changes
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.95 · Median 0.70 · Most common event other_material